Neurowave Medical Technologies™ (NMT) develops, manufactures and commercializes advanced nerve stimulation therapeutic medical devices for the treatment of a wide range of clinical conditions and numerous acute and chronic diseases. NMT™ was founded in 2007 with the acquisition of all global rights, corporate assets, technology, trademarks, and intellectual property of Woodside Biomedical, Inc., a wholly-owned subsidiary of Abbott Laboratories.
Healthcare professionals, patients, and payors are seeking new treatment alternatives that provide demonstrated therapeutic benefits and economic value that can replace current pharmaceutical therapies.
As such, NMT’s mission is to develop high-quality, innovative medical devices using its patented and proprietary Nerve Stimulation Therapy™ technology platform to treat various acute and chronic medical conditions that up to this point have required significant medications for relief, or surgical intervention to control.
NMT’s medical devices are a revolution in healthcare in that, for the first time, they can offer a safe treatment option for clinical conditions on par with pharmaceutical products in both clinical efficacy and cost, but without the complications or side effects associated with medications. In fact, NMT’s devices go beyond traditional pharmaceutical products by allowing patients and healthcare providers to take complete control over the administration of their therapy and the immediate relief of their symptoms when they occur.
